Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
Editor's Blog and Industry Comments

Israel’s scientific ethos driving pharma industry value beyond $2.3 billion by 2020

01 January, 2015
Israel’s pharmaceutical market value will increase from approximately $1.9 billion in 2013 to $2.34 billion by 2020, driven by medical technology advances, high research and development (R&D) expenditure and a robust economy, according to research and consulting firm GlobalData.

Globaldata's latest report states that this rise, which represents a modest Compound Annual Growth Rate (CAGR) of 2.8%, will occur in a country with high levels of generic production and pharmaceutical exports.


 


Israel is home to Teva Pharmaceuticals, which is one of the world’s largest generics manufacturers and exporters. The country’s entire pharmaceutical exports were worth approximately $7.1 billion in 2013, more than four times the value of its imports, which was just over $1.7 billion.


 


Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “Israel is one of the major healthcare markets in the Middle East. “Pharmaceuticals represent the largest and most established sector of the Israeli life science industry, with a total of 76 companies, of which 22% are involved in drug discovery and 17% in drug delivery.” The director adds that this commitment to scientific development is fortified by a highly skilled population, with Invest in Israel highlighting that the country is ranked second in the world for percentage of engineers and scientists in the workforce. Owide continues: “Approximately 24% of Israel’s workers hold university degrees, placing it third among the industrialized countries, after the US and Netherlands.


 


“Israel’s pharmaceutical sector is supported by a network of recognized academic and research institutes, R&D facilities, and well-developed medical centers. Indeed, Israeli research expertise and clinical advances have led to the development of blockbuster drugs and promising treatments.”


 


Such products include Johnson and Johnson’s Doxil for ovarian cancer, which was originally developed at the Hadassah Medical Center, as well as Teva Pharmaceuticals and the Weizmann Institute’s Copaxone for multiple sclerosis, and Novartis’ Exelon for Alzheimer’s disease, originating from research conducted at the Hebrew University.


 


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo